Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2016

Imamura Fumio, Uchida Junji, Kukita Yoji, Kumagai Toru, Nishino Kazumi, Inoue Takako, Kimura Madoka, Oba Shigeyuki, Kato Kikuya

Abstract excerpt

OBJECTIVES: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have dramatic effects on EGFR-mutant non-small-cell lung cancer (NSCLC). However, most patients experience disease recurrences, approximately half of which are T790M-mediated. Monitoring EGFR status with re-biopsy has spatiotemporal limitations. PATIENTS AND METHODS: EGFR circulating tumor DNA (ctDNA) in serial plasma samples was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clonal Evolution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Identifiers

PMID: 26973209
DOI: 10.1016/j.lungcan.2016.01.023

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.PMID 26973209Read ↗

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.Semantic proximity Read ↗

Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment.Semantic proximity Read ↗

Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatmentSemantic proximity Read ↗

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs.Semantic proximity Read ↗

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.Semantic proximity Read ↗

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read ↗

Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma.Semantic proximity Read ↗

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.Semantic proximity Read ↗

Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.Semantic proximity Read ↗

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.